|
SECURITIES AND EXCHANGE COMMISSION |
|
|
|
FORM 8-K |
|
|
|
|
|
________________ |
|
|
|
Alpharma Inc. |
||
|
(Exact name of registrant as specified in its charter) |
||
|
Delaware (State or other jurisdiction of incorporation) |
1-8593 (Commission File Number) |
22-2095212 (IRS Employer Identification) |
|
One Executive Drive, Fort Lee, New Jersey 07024 |
|
Registrant's telephone number, including area code |
|
Not Applicable |
|
______________________________________________ |
|
last report) |
Item 1.01 Entry into a Definitive Material Agreement
On February 23, 2005, Purepac Pharmaceutical Co. ("Company"), a wholly-owned subsidiary of Alpharma Inc., and Orchid Chemicals & Pharmaceuticals, Ltd. ("Orchid"), entered into a Master Development, Manufacturing, Supply and Marketing Agreement, effective February 23, 2005, pursuant to which Orchid has agreed to (i) develop active pharmaceutical ingredients and final formulations and (ii) manufacture finished products, for exclusive sale by the Company in the US, Canada and Europe. During the period of exclusive sales by the Company, Orchid will be entitled to a portion of the profits on these sales. Additionally, the Agreement provides for Alpharma to make milestone payments to Orchid upon certain significant events. Ten products, with launch dates commencing in 2007, have been initially selected for this arrangement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ALPHARMA INC. |
|
|
By: /s/ Robert F. Wrobel |
|
|
Name: Robert F. Wrobel Title: Executive Vice President and CLO |
Date: February 28, 2005